A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

Owen A. O'Connor, A. Keith Stewart, Marcy Vallone, Christopher J. Molineaux, Lori A. Kunkel, John F. Gerecitano, Robert Z. Orlowski

Research output: Contribution to journal › Article › peer-review

243 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences